Navigation Links
Chemizon Announces Research Collaboration Expansion With Takeda
Date:10/1/2007

LONGMONT, Colo., Oct. 1 /PRNewswire/ -- Chemizon (010170, KOSDAQ) announced today that it has reached an agreement with Takeda Pharmaceutical Company Limited, to expand its current research collaboration focused on utilizing Chemizon's discovery platform.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070606/LAW174LOGO)

As part of the agreement, Chemizon will commit a majority of its current Korean site to the Takeda partnership. In addition, Chemizon will expand its Korean operations to accommodate future growth.

"Takeda is a premier global pharmaceutical company and we are delighted that they have chosen Chemizon as a preferred partner," said Dr. Tony Piscopio, Chairman and CEO of Chemizon. "Our highly motivated scientific team's commitment to excellence remains the foundation for Chemizon's rapid growth. As we add biology capabilities to our integrated discovery platform, our partners will be able to leverage a number of additional options that will become available in the near future."

About Chemizon Inc.:

Chemizon, a division of Optomagic Co. Ltd., is a global provider of drug discovery and development capabilities to the pharmaceutical industry. Anchored by an experienced management team, Chemizon combines its vertically integrated discovery platform with a flexible, collaborative business model to develop best-in-class clinical candidates. Our expertise spans a broad range of therapeutic areas and target classes. In addition to providing an integrated discovery solution, we assist our collaborators with stand alone services including: lead optimization, library design and synthesis, custom synthesis, radiolabeling, ADME profiling, analytical method development and process chemistry.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

Forward-looking statements

This press release may contain certain "forward-looking statements" regarding the agreement between Chemizon and Takeda Pharmaceutical Company Limited. These statements are based on Chemizon's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, collaboration potential or financial performance. None of the forward-looking statements are guaranteed, and actual results may differ materially from those projected. Chemizon may choose to update this notice in the future, based on new information, future events, or otherwise, but undertakes no obligation to do so. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Chemizon's business, including, but not limited to, the health of the global life sciences industry, the growth of the outsourcing business model and the ability of Chemizon to derive value from successful collaborations.


'/>"/>
SOURCE Chemizon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: